Country：Japan

Authorship：Principal investigator  Grant type：Scientific research funding

全身性エリテマトーデス（SLE）の治療は、これまでステロイド内服などの免疫抑制剤が治療の主体であったが、近年ステロイドを減薬させることができるような、長期的に安全な新規治療薬の開発が望まれている。炎症性皮膚疾患の新たな治療ターゲットとして、AHR（Aryl hydrocarbon receptor; 芳香族炭化水素受容体）が注目されている。本研究ではAHRをターゲットとしたSLE皮疹に対する新たな治療法の開発を目指す。

CiNii Research

Authorship：Principal investigator  Grant type：Scientific research funding

The activation kinetics of the AHR, NRF2, and EGFR pathways were examined in NHEK when autophagy was induced, inhibited, or LAP inhibited. It was determined that CYP1A1 tended to increase regardless of autophagy/LAP, which may be due to reagent characteristics, and that autophagy/LAP balance and activation of the AHR could not be evaluated with autophagy inducers/inhibitors or LAP inhibitors. Stimulation of keratinocytes with synthetic nucleic acid and IFNα resulted in the appearance of SLE skin rash-like signals. Further treatment with AHR ligand showed suppression of some of the above SLE-like skin rash signals.

CiNii Research